The Molecular Pathology of Non-Malignant Haematological Disease
-
By
-
A. D. Blann
-
R. G. Dunn
-
May 22, 2026
-
Clinical Scorecard: Molecular Pathology Insights into Non-Malignant Hematological Disorders
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Genetic mutations affecting red blood cells, including haemoglobinopathies and enzymopathies. |
| Target Population | Individuals with genetic predispositions to hematological disorders, including sickle cell disease and thalassemia. |
| Care Setting | Clinical and diagnostic laboratories specializing in hematology and molecular pathology. |
Key Highlights
- Haemoglobinopathies are the most prevalent non-malignant hematological disorders.
- Sickle cell disease affects approximately 3 million people globally.
- G6PD deficiency is recognized as a significant public health issue.
Guideline-Based Recommendations
Diagnosis
- Utilize molecular genetics techniques for accurate diagnosis of haemoglobinopathies.
Management
- Consider targeted therapeutic options based on genetic findings.
Monitoring & Follow-up
- Regular assessment of genetic mutations and their clinical implications.
Risks
- Increased morbidity associated with haemoglobinopathies and related disorders.
Patient & Prescribing Data
Individuals diagnosed with haemoglobinopathies and related genetic disorders.
Gene therapy and targeted treatments based on specific genetic mutations are emerging.
Clinical Best Practices
- Implement comprehensive genetic testing for patients with suspected hematological disorders.
- Educate patients on the implications of genetic findings for management and family planning.
- Collaborate with genetic counselors for patient support and education.
Related Resources & Content
